Tofacitinib for refractory uveitis and scleritis

Michael A. Paley; Humeyra Karacal; P. Kumar Rao; Todd P. Margolis; Jonathan J. Miner

doi:10.1016/j.ajoc.2018.12.001

Tofacitinib for refractory uveitis and scleritis

Michael A. Paley, Humeyra Karacal, P. Kumar Rao, Todd P. Margolis, Jonathan J. Miner

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Abstract

Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. Conclusions and importance: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.

Original language	English
Pages (from-to)	53-55
Number of pages	3
Journal	American Journal of Ophthalmology Case Reports
Volume	13
DOIs	https://doi.org/10.1016/j.ajoc.2018.12.001
State	Published - Mar 2019

Keywords

JAK
STAT
Scleritis
Tofacitinib
Uveitis

Access to Document

10.1016/j.ajoc.2018.12.001

Cite this

@article{fecee00a460d4aa1b0c881f59d94bdff,

title = "Tofacitinib for refractory uveitis and scleritis",

abstract = "Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. Conclusions and importance: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.",

keywords = "JAK, STAT, Scleritis, Tofacitinib, Uveitis",

author = "Paley, {Michael A.} and Humeyra Karacal and Rao, {P. Kumar} and Margolis, {Todd P.} and Miner, {Jonathan J.}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = mar,

doi = "10.1016/j.ajoc.2018.12.001",

language = "English",

volume = "13",

pages = "53--55",

journal = "American Journal of Ophthalmology Case Reports",

issn = "2451-9936",

}

TY - JOUR

T1 - Tofacitinib for refractory uveitis and scleritis

AU - Paley, Michael A.

AU - Karacal, Humeyra

AU - Rao, P. Kumar

AU - Margolis, Todd P.

AU - Miner, Jonathan J.

PY - 2019/3

Y1 - 2019/3

N2 - Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. Conclusions and importance: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.

AB - Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure of multiple steroid-sparing therapies. Treatment with tofacitinib led to durable resolution of uveitis and scleritis. Conclusions and importance: Tofacitinib is a potential novel treatment option for refractory, noninfectious inflammatory eye disease.

KW - JAK

KW - STAT

KW - Scleritis

KW - Tofacitinib

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=85057714554&partnerID=8YFLogxK

U2 - 10.1016/j.ajoc.2018.12.001

DO - 10.1016/j.ajoc.2018.12.001

M3 - Article

C2 - 30582071

AN - SCOPUS:85057714554

SN - 2451-9936

VL - 13

SP - 53

EP - 55

JO - American Journal of Ophthalmology Case Reports

JF - American Journal of Ophthalmology Case Reports

ER -

Tofacitinib for refractory uveitis and scleritis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this